Header Logo

Connection

Lynn Morris to Viral Load

This is a "connection" page, showing publications Lynn Morris has written about Viral Load.
Connection Strength

1,921
  1. HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. PLoS One. 2020; 15(6):e0234937.
    View in: PubMed
    Score: 0,526
  2. Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. mSphere. 2020 Jan 29; 5(1).
    View in: PubMed
    Score: 0,128
  3. Evidence for both Intermittent and Persistent Compartmentalization of HIV-1 in the Female Genital Tract. J Virol. 2019 05 15; 93(10).
    View in: PubMed
    Score: 0,122
  4. Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol. 2015 Apr; 23(4):204-11.
    View in: PubMed
    Score: 0,090
  5. Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study. Trop Med Int Health. 2014 Feb; 19(2):236-9.
    View in: PubMed
    Score: 0,085
  6. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis. 2014 Mar 01; 209(5):711-20.
    View in: PubMed
    Score: 0,082
  7. Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. Antivir Ther. 2013; 18(7):915-20.
    View in: PubMed
    Score: 0,081
  8. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol. 2011 May; 85(10):4828-40.
    View in: PubMed
    Score: 0,069
  9. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study. BMC Public Health. 2011 Feb 08; 11:88.
    View in: PubMed
    Score: 0,069
  10. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010 Jul 17; 24(11):1679-87.
    View in: PubMed
    Score: 0,066
  11. Does tuberculosis increase HIV load? J Infect Dis. 2004 Nov 01; 190(9):1677-84.
    View in: PubMed
    Score: 0,044
  12. High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nat Commun. 2023 Dec 14; 14(1):8299.
    View in: PubMed
    Score: 0,042
  13. Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis. 2003 Jun 15; 187(12):1967-71.
    View in: PubMed
    Score: 0,040
  14. Infection of Chinese Rhesus Monkeys with a Subtype C SHIV Resulted in Attenuated In Vivo Viral Replication Despite Successful Animal-to-Animal Serial Passages. Viruses. 2021 03 02; 13(3).
    View in: PubMed
    Score: 0,035
  15. Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected Children. Front Immunol. 2019; 10:1497.
    View in: PubMed
    Score: 0,031
  16. High human immunodeficiency virus type 1 RNA load in the cerebrospinal fluid from patients with lymphocytic meningitis. J Infect Dis. 1998 Feb; 177(2):473-6.
    View in: PubMed
    Score: 0,028
  17. Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa. J Antimicrob Chemother. 2017 Nov 01; 72(11):3141-3148.
    View in: PubMed
    Score: 0,027
  18. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci Transl Med. 2017 09 06; 9(406).
    View in: PubMed
    Score: 0,027
  19. Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection. Sci Transl Med. 2016 09 28; 8(358):358ra125.
    View in: PubMed
    Score: 0,025
  20. Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. Lancet Infect Dis. 2015 Jul; 15(7):803-9.
    View in: PubMed
    Score: 0,023
  21. Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa. J Infect Dis. 2015 May 01; 211(9):1461-6.
    View in: PubMed
    Score: 0,022
  22. Rapid disease progression in HIV-1 subtype C-infected South African women. Clin Infect Dis. 2014 Nov 01; 59(9):1322-31.
    View in: PubMed
    Score: 0,022
  23. Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania. J Infect Dev Ctries. 2014 Jul 14; 8(7):845-52.
    View in: PubMed
    Score: 0,022
  24. Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial. J Infect Dis. 2014 Jun 15; 209(12):1916-20.
    View in: PubMed
    Score: 0,021
  25. Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology. 2012 Nov 25; 433(2):410-20.
    View in: PubMed
    Score: 0,019
  26. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Jul; 12(7):521-30.
    View in: PubMed
    Score: 0,019
  27. Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):304-8.
    View in: PubMed
    Score: 0,018
  28. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS. 2011 Jul 31; 25(12):1461-9.
    View in: PubMed
    Score: 0,018
  29. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):945-56.
    View in: PubMed
    Score: 0,017
  30. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010 Sep 03; 329(5996):1168-74.
    View in: PubMed
    Score: 0,017
  31. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009 Feb 15; 48(4):462-72.
    View in: PubMed
    Score: 0,015
  32. Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point. J Virol. 2009 Jan; 83(1):470-8.
    View in: PubMed
    Score: 0,015
  33. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS. 2008 Jul 11; 22(11):1333-43.
    View in: PubMed
    Score: 0,014
  34. Use of a novel washing method combining multiple density gradients and trypsin for removing human immunodeficiency virus-1 and hepatitis C virus from semen. Fertil Steril. 2005 Oct; 84(4):1001-10.
    View in: PubMed
    Score: 0,012
  35. Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. AIDS Res Hum Retroviruses. 2005 Apr; 21(4):285-91.
    View in: PubMed
    Score: 0,011
  36. Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis. 2004 Oct 01; 190(7):1355-9.
    View in: PubMed
    Score: 0,011
  37. Dual infective pathology in patients with cryptococcal meningitis. Neurology. 1998 Oct; 51(4):1213-5.
    View in: PubMed
    Score: 0,007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.